Cancer Progress: Much More Than You Wanted To Know

An MMTYWTK adjudicating whether we're 'winning the War on Cancer' against the skeptical view that rising survival rates are a screening artifact (lead-time/length bias). Scott works it carefully: (1) age-adjusted incidence/death rates rose to 1990 then fell, but the fall is mostly PREVENTION — the cancer curve is the smoking curve plus a 20-30-year lag, with prostate (over-screening), stomach (h. pylori), colon (colonoscopy) etc. layered on. (2) Five-year-survival gains correlate with incidence (detection), not death rate (Welch/Schwartz/Woloshin) — the lead-time-bias worry. (3) BUT stage-specific survival rose too (SEER), and even adjusting for tumor SIZE within stage the gains largely persist (Elkin: size explains only 61%/28% of localized/regional breast gains; Tong: stage/size explains only 20% of colon gains, therapy ~71%); the lone contrary case (laryngeal) is 1 of 24. Conclusion: adjusting for everything monitorable, treatment really has improved (screening explains maybe 20-50%, real treatment gains the rest) — modest but non-zero, honestly framed against the older generation's Nixon-era 'cure in five years' disappointment.

Quality 76 · Excellent. An excellent, rigorous adjudication of a genuinely contested empirical question — the lead-time-bias -> stage-specific -> size-adjusted chain is sophisticated, clearly explained, and balanced, earning its modest-but-real conclusion. Excellent-low; shorter/narrower than the top MMTYWTKs, which holds it just inside the band.

Claude’s paradigm shift 56 · Moderate. A careful synthesis of others' studies adjudicating the screening-bias confound; sharp but it reviews rather than originates the evidence. Notable.

Real-world impact 2 · Minor. A within-discourse public-understanding-of-cancer-progress piece; no material-world effect. Within-blog influence.